Last data update: Dec 02, 2024. (Total: 48272 publications since 2009)
Records 1-3 (of 3 Records) |
Query Trace: Calero L[original query] |
---|
Evaluating predictive relationships between wristbands and urine for assessment of personal PAH exposure.
Dixon HM , Bramer LM , Scott RP , Calero L , Holmes D , Gibson EA , Cavalier HM , Rohlman D , Miller RL , Calafat AM , Kincl L , Waters KM , Herbstman JB , Anderson KA . Environ Int 2022 163 107226 During events like the COVID-19 pandemic or a disaster, researchers may need to switch from collecting biological samples to personal exposure samplers that are easy and safe to transport and wear, such as silicone wristbands. Previous studies have demonstrated significant correlations between urine biomarker concentrations and chemical levels in wristbands. We build upon those studies and use a novel combination of descriptive statistics and supervised statistical learning to evaluate the relationship between polycyclic aromatic hydrocarbon (PAH) concentrations in silicone wristbands and hydroxy-PAH (OH-PAH) concentrations in urine. In New York City, 109 participants in a longitudinal birth cohort wore one wristband for 48 h and provided a spot urine sample at the end of the 48-hour period during their third trimester of pregnancy. We compared four PAHs with the corresponding seven OH-PAHs using descriptive statistics, a linear regression model, and a linear discriminant analysis model. Five of the seven PAH and OH-PAH pairs had significant correlations (Pearson's r = 0.35-0.64, p ≤ 0.003) and significant chi-square tests of independence for exposure categories (p ≤ 0.009). For these five comparisons, the observed PAH or OH-PAH concentration could predict the other concentration within a factor of 1.47 for 50-80% of the measurements (depending on the pair). Prediction accuracies for high exposure categories were at least 1.5 times higher compared to accuracies based on random chance. These results demonstrate that wristbands and urine provide similar PAH exposure assessment information, which is critical for environmental health researchers looking for the flexibility to switch between biological sample and wristband collection. |
Silicone wristbands compared with traditional polycyclic aromatic hydrocarbon exposure assessment methods
Dixon HM , Scott RP , Holmes D , Calero L , Kincl LD , Waters KM , Camann DE , Calafat AM , Herbstman JB , Anderson KA . Anal Bioanal Chem 2018 410 (13) 3059-3071 Currently there is a lack of inexpensive, easy-to-use technology to evaluate human exposure to environmental chemicals, including polycyclic aromatic hydrocarbons (PAHs). This is the first study in which silicone wristbands were deployed alongside two traditional personal PAH exposure assessment methods: active air monitoring with samplers (i.e., polyurethane foam (PUF) and filter) housed in backpacks, and biological sampling with urine. We demonstrate that wristbands worn for 48 h in a non-occupational setting recover semivolatile PAHs, and we compare levels of PAHs in wristbands to PAHs in PUFs-filters and to hydroxy-PAH (OH-PAH) biomarkers in urine. We deployed all samplers simultaneously for 48 h on 22 pregnant women in an established urban birth cohort. Each woman provided one spot urine sample at the end of the 48-h period. Wristbands recovered PAHs with similar detection frequencies to PUFs-filters. Of the 62 PAHs tested for in the 22 wristbands, 51 PAHs were detected in at least one wristband. In this cohort of pregnant women, we found more significant correlations between OH-PAHs and PAHs in wristbands than between OH-PAHs and PAHs in PUFs-filters. Only two comparisons between PAHs in PUFs-filters and OH-PAHs correlated significantly (rs = 0.53 and p = 0.01; rs = 0.44 and p = 0.04), whereas six comparisons between PAHs in wristbands and OH-PAHs correlated significantly (rs = 0.44 to 0.76 and p = 0.04 to <0.0001). These results support the utility of wristbands as a biologically relevant exposure assessment tool which can be easily integrated into environmental health studies. Graphical abstract PAHs detected in samples collected from urban pregnant women. |
Clinical cancer advances 2016: Annual report on progress against cancer from the American Society of Clinical Oncology
Dizon DS , Krilov L , Cohen E , Gangadhar T , Ganz PA , Hensing TA , Hunger S , Krishnamurthi SS , Lassman AB , Markham MJ , Mayer E , Neuss M , Pal SK , Richardson LC , Schilsky R , Schwartz GK , Spriggs DR , Villalona-Calero MA , Villani G , Masters G . J Clin Oncol 2016 34 (9) 987-1011 The past few years have been incredibly exciting in cancer research and care. Some of the advances highlighted in Clinical Cancer Advances 2016 are already improving the lives of patients today, and many others provide direction for further research. | Compared with when I started my career in oncology, today we do the unthinkable. We no longer treat cancer simply by its type or stage. In the era of precision medicine, we select—and rule out—treatments based the genomic profile of each patient and the tumor. We manage once-debilitating adverse effects to the point that many, if not most, patients can continue their daily activities during treatment. | No recent advance has been more transformative than the rise of immunotherapy, particularly over this past year, making immunotherapy the American Society of Clinical Oncology’s (ASCO’s) Advance of the Year. | The immunotherapy concept is simple: unleash the body’s immune system to attack cancer. It has proven extremely difficult, however, to develop treatments that deliver real, consistent results. Decades of bold ideas, dedication, and financial investment in research have been required to prove immunotherapy’s worth as a treatment for people with an array of different cancers. |
- Page last reviewed:Feb 1, 2024
- Page last updated:Dec 02, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure